NFKB1 and urinary bladder cancer: NF-κB inhibitors, such as the dehydroxymethyl derivative of epoxyquinomicin (DHMEQ), have been shown to induce tumor growth suppression and overcome cisplatin resistance in bladder cancer models [71].